علم الأورام (طبي)

بالأسفل التجارب السريرية الحالية.

غربل قائمة الدراسات هذه بالموقع والحالة وغيرها.

1. Global Cardio Oncology Registry

   Rochester, Minn.

   The purpose of this study is to provide a large database and platform for prospective sub-studies and eventually develop additional collaborations with a platform for clinical studies and trials following the initial pilot phase.

2. AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL

   Rochester, Minn.

   This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for DLBCL.

3. EF-41/KEYNOTE D58: Phase 3 Study Of Optune Concomitant With Temozolomide Plus Pembrolizumab In Newly Diagnosed Glioblastoma

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).

4. A Feasibility Study To Evaluate The Safety Of The TheraSphere Glioblastoma (GBM) Device In Patients With Recurrent GBM

   Jacksonville, Fla.

   The purpose of this study is to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent glioblastoma (GBM).

5. A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

   Jacksonville, Fla.

   The purpose of phase 2a is to establish proof-of-concept (POC) for AG-946 in participants with lower-risk myelodysplastic syndromes (LR-MDS) and to evaluate the safety, effect, and pharmacokineticsof AG-946 on additional measures of anemia. Additionally to evaluate the effect of AG-946 on transfusion burden (participants with LTB only) and the effect of AG-946 on pharmacodynamic biomarkers.

   The purpose of phase 2b is to compare the effect of AG-946 versus placebo and to detect a doseresponse for erythroid response in participants with LR-MD

6. A Prospective Ocular Tumor Study

   Rochester, Minn.

   The purpose of this study is to use clinical, imaging, molecular, and epidemiological investigation toward the goal of providing new knowledge about ocular tumors that will be useful in understanding, diagnosing, monitoring, and suggesting new avenues of treatment. This study does not involve experimental treatment of any ocular tumor, but rather observation of tumor natural history or outcomes following standard of care therapy, associated systemic and ocular conditions, and basic research investigations to better understand tumor biomarkers and pathophysiology.

7. Defining the Immunologic Profile of Sentinel Lymph Nodes and Identifying the Mechanisms Responsible for Immunosuppression

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to look at the effects cancer and melanoma have on the immune cells found in lymph nodes.

8. A Study Evaluating the Safety and Effectiveness of Therapies in Patients with Metastatic Colorectal Cancer (INTRINSIC)

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.